SAGE Therapeutics (SAGE) Downgraded by BidaskClub to Strong Sell

SAGE Therapeutics (NASDAQ:SAGE) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday.

A number of other analysts also recently weighed in on SAGE. LADENBURG THALM/SH SH started coverage on shares of SAGE Therapeutics in a research report on Wednesday, June 6th. They set a “buy” rating and a $230.00 target price for the company. Canaccord Genuity reissued a “buy” rating and set a $220.00 target price on shares of SAGE Therapeutics in a research report on Tuesday, June 12th. Cowen reaffirmed a “buy” rating and set a $207.00 price objective on shares of SAGE Therapeutics in a research report on Thursday, June 14th. Morgan Stanley raised their price objective on shares of SAGE Therapeutics from $225.00 to $228.00 and gave the stock an “overweight” rating in a research report on Friday, July 13th. Finally, Piper Jaffray Companies began coverage on shares of SAGE Therapeutics in a research report on Monday, August 6th. They set an “overweight” rating and a $206.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $199.19.

NASDAQ:SAGE opened at $148.37 on Friday. The company has a market cap of $6.98 billion, a price-to-earnings ratio of -20.93 and a beta of 2.90. SAGE Therapeutics has a fifty-two week low of $59.57 and a fifty-two week high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.84) by $1.48. The firm had revenue of $90.00 million for the quarter. equities research analysts forecast that SAGE Therapeutics will post -7.37 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of the business. CIBC Asset Management Inc lifted its stake in SAGE Therapeutics by 26.4% during the 2nd quarter. CIBC Asset Management Inc now owns 1,633 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 341 shares in the last quarter. Prudential Financial Inc. increased its position in shares of SAGE Therapeutics by 9.5% during the 1st quarter. Prudential Financial Inc. now owns 4,220 shares of the biopharmaceutical company’s stock valued at $680,000 after purchasing an additional 366 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of SAGE Therapeutics by 3.2% during the 1st quarter. Principal Financial Group Inc. now owns 12,406 shares of the biopharmaceutical company’s stock valued at $1,998,000 after purchasing an additional 382 shares during the last quarter. BTG Pactual Global Asset Management Ltd increased its position in shares of SAGE Therapeutics by 12.4% during the 2nd quarter. BTG Pactual Global Asset Management Ltd now owns 4,015 shares of the biopharmaceutical company’s stock valued at $628,000 after purchasing an additional 442 shares during the last quarter. Finally, Neuberger Berman Group LLC increased its position in shares of SAGE Therapeutics by 15.3% during the 1st quarter. Neuberger Berman Group LLC now owns 3,459 shares of the biopharmaceutical company’s stock valued at $557,000 after purchasing an additional 459 shares during the last quarter.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Further Reading: Leveraged Buyout (LBO) Explained

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply